Role of Insulin Analogs in Type 2 Diabetes
References
1. American Association of Clinical Endocrinologists/American College of Endocrinology Diabetes Recommendations Implementation Writing Committee. ACE/AACE Consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference
recommendations. Endocr Pract. 2006;12:(Suppl 1):6–12.
2. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract.
2000;6:162–213.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1): S62–S69.
4. American Diabetes Association. Estimated average glucose, eAG. Available at:
http://professional.diabetes.org/GlucoseCalculator.aspx. Accessed December 16, 2009. 5. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care.
2010;33(Suppl 1):S11–S61.
6. Apidra® (insulin glulisine [rDNA origin] injection) solution for injection. Prescribing information. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2008.
7. Bardsley JK, Ratner RE. Pathophysiology of the metabolic disorder. In: Mensing C, ed: The Art and Science of Diabetes Self-Management Education. Chicago, Ill: American Association of Diabetes Educators; 2006:143–161.
8. Bergenstal RM, Kendall DM, Franz MJ, et al. Management of type 2 diabetes: a systematic approach to meeting standards of care. II: Oral agents, insulin and management of complications. In: DeGroot, LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia, Pa: WB Saunders Co; 2001:822.
9. Blonde L, Merilainen M, Karwe V, et al; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two
different fasting plasma glucose targets—the TITRATE™ Study. Diabetes Obes Metab.
2009;11:623–631.
10.Buse JB, Wolffenbuttel BHR, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
Diabetes Care. 2009;32:1007–1013.
11.Centers for Disease Control and Prevention. Division of Diabetes Translation. National Diabetes Surveillance System. Atlanta, Ga: Centers for Disease Control and Prevention; 2009. Available at: http://www.cdc.gov/diabetes/statistics. Accessed December 15, 2009.
Role of Insulin Analogs in Type 2 Diabetes
References
12.Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. Atlanta, Ga: Centers for Disease Control and Prevention; 2009. Available at:
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed December 15, 2009.
13.Centers for Disease Control and Prevention. State-specific incidence of diabetes among adults – participating states, 1995–1997 and 2005–2007. MMWR. 2008;57:1169–1173.
14.Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902–1912.
15.Foulis AK, Clark A. Pathology of the pancreas in diabetes mellitus. In: Kahn DR, Weir GC, eds.
Joslin’s Diabetes Mellitus. 13th ed. Philadelphia, Pa: Lea & Febiger;1994:265–281.
16.Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006;8:58–66.
17.Gavin JR III. Practical approaches to insulin therapy. Diabetes Educ. 2007;33(Suppl 3):66S–73S.
18.Hermansen K, Davies M, Derezinski T, et al; on Behalf of the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269–1274.
19.Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143:559–569.
20.Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78–86.
21.Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81–86.
22.Holman RR, Farmer AJ, Davies MJ, et al; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747.
23.Humalog® Mix50/50™ (50% insulin lispro protamine suspension and 50% insulin lispro injection [rDNA origin]). Prescribing information. Indianapolis, Ind: Eli Lilly and Company; 2007.
24.Humulin® N (NPH, human insulin [rDNA origin] isophane suspension). Prescribing information. Indianapolis, Ind: Eli Lilly and Company; 2000.
25.Kazlauskaite R, Fogelfeld L. Insulin therapy in type 2 diabetes. Dis Mon. 2003;49:377–420.
26.Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes. Diabetes Care. 2007;30:707–712.
Role of Insulin Analogs in Type 2 Diabetes
References
27.Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J ObesRelat Metab Disord. 2002;26(Suppl 3):S18–S24.
28.Lantus® (insulin glargine [rDNA origin] injection). Prescribing information. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2007.
29.Lebovitz HE. Diagnosis and classification of diabetes mellitus. In: Lebovitz HE, ed. Therapy for Diabetes Mellitus and Related Disorders. 4th ed. Alexandria, Va: American Diabetes Association; 2004:5–7.
30.Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of
subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142– 2148.
31.Levemir® (insulin detemir [rDNA origin] injection). Prescribing information. Princeton, NJ: Novo Nordisk Inc.; 2007.
32.Lingvay I, Legendre JL, Kaloyanova PF, et al. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better. Diabetes Care. 2009;32:1789–1795.
33.Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034–2044.
34.Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2
diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
35.Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473–1478.
36.Novolin® N (NPH, human insulin isophane suspension [rDNA origin]). Prescribing information. Princeton, NJ; Novo Nordisk Inc.; 1999.
37.Pearson J, Powers MA. Systematically initiating insulin: the staged diabetes management approach. Diabetes Educ. 2006;32(Suppl):19S–28S.
38.Peragallo-Dittko V. Removing barriers to insulin therapy. Diabetes Educ. 2007;33:60S–65S.
39.Peyrot M, Mathews DR, Snoek FJ, et al. An international study of psychological resistance to insulin among persons with diabetes. Diabetologia. 2003;46(Suppl 2):A89.
40.Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Diabetes Care. 2005;28:2673–2679.
Role of Insulin Analogs in Type 2 Diabetes
References
41.Phillips P. Type 2 diabetes—failure, blame and guilt in the adoption of insulin therapy. Rev. Diabet Stud. 2005;2:35–39.
42.Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care. 2005;28:2543–2545.
43.Polonsky WH, Jackson RA. What’s so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22:147–150.
44.Raskin P, Allen E, Hollander P, et al; for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260– 265.
45.Ratner R. Insulin delivery systems and the management of diabetes. Pract Diabetol. 2004;23:14– 24.
46.Raz I, Wilson PWF, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:381–386.
47.Riddle MC, Rosenstock J, Gerich J; on Behalf of the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086.
48.Robertson C. Physiologic insulin replacement in type 2 diabetes: Optimizing postprandial glucose control. Diabetes Educator. 2006;32:423–432.
49.Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes
mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:542–559.
50.Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297:137–140.
51.Sanofi-aventis. Clinical trial summary: NCT00405418. Target glycemic control and the incidence of documented symptomatic hypoglycemia in insulin naïve subjects with type 2 diabetes failing on oral hypoglycemic agent(s) and treated with Lantus® (insulin glargine) or Levemir® (insulin
detemir): a multicenter, multinational, randomized, open-label, comparative, parallel-group study. Available at: http://www.clinicalstudyresults.org/documents/company-study_9127_0.pdf.
Accessed January 27, 2010.
52.Skyler JS. Insulin treatment. In: Lebovitz HE, ed. Therapy for Diabetes Mellitus and Related Disorders. Alexandria, Va: American Diabetes Association; 2004:207–223.
53.Steil CF. Pharmacologic therapies for glucose management. In: Mensing C, ed. The Art and Science of Diabetes Self-Management Education. Chicago, Ill: American Association of Diabetes Educators; 2006:321–355.
Role of Insulin Analogs in Type 2 Diabetes
References
54.Swinnen SG, Snoek FJ, Dain MP, et al. Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) treat-to-target (L2T3) study: a multinational,
randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technol Ther. 2009;11:739–743.
55.Thorn LM, Forsblom C, Fagerudd J, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28:2019– 2024.
56.Tomky DM, Kulkarni K. Intensifying insulin therapy: multiple daily injections to pump therapy. In: Mensing C, ed. The Art and Science of Diabetes Self-Management Education. Chicago, Ill: American Association of Diabetes Educators; 2006:371–398.
57.Welchol (colesevelam hydrochloride). Prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc.; 2009.
